TR201819564T4 - Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. - Google Patents
Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.Info
- Publication number
- TR201819564T4 TR201819564T4 TR2018/19564T TR201819564T TR201819564T4 TR 201819564 T4 TR201819564 T4 TR 201819564T4 TR 2018/19564 T TR2018/19564 T TR 2018/19564T TR 201819564 T TR201819564 T TR 201819564T TR 201819564 T4 TR201819564 T4 TR 201819564T4
- Authority
- TR
- Turkey
- Prior art keywords
- related disorders
- cmt
- treatment
- novel therapeutic
- therapeutic approaches
- Prior art date
Links
- 238000013459 approach Methods 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 abstract 1
- 101001000631 Homo sapiens Peripheral myelin protein 22 Proteins 0.000 abstract 1
- 101001082860 Homo sapiens Peroxisomal membrane protein 2 Proteins 0.000 abstract 1
- 102100030564 Peroxisomal membrane protein 2 Human genes 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Mevcut buluş, Charcot-Marie-Tooth hastalığı ve ilgili bozuklukların tedavisi için bileşimlerle ve yöntemlerle ilgilidir. Daha spesifik olarak, buluş söz konusu hastalığın sujede PMP22 ekspresyonunun azaltılması aracılığıyla tedavi edilmesi için kombine tedavilerle ilgilidir.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07301614A EP2065038A1 (en) | 2007-11-30 | 2007-11-30 | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
US99180007P | 2007-12-03 | 2007-12-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
TR201819564T4 true TR201819564T4 (tr) | 2019-01-21 |
Family
ID=39264515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2018/19564T TR201819564T4 (tr) | 2007-11-30 | 2008-11-28 | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. |
Country Status (24)
Country | Link |
---|---|
US (6) | US8992891B2 (tr) |
EP (4) | EP2065038A1 (tr) |
JP (4) | JP5953000B2 (tr) |
KR (1) | KR101546031B1 (tr) |
CN (2) | CN104257657B (tr) |
AU (1) | AU2008328745B2 (tr) |
BR (1) | BRPI0819678A2 (tr) |
CA (3) | CA3031484C (tr) |
CY (2) | CY1113980T1 (tr) |
DK (2) | DK2609916T3 (tr) |
EA (3) | EA035711B1 (tr) |
ES (3) | ES2408785T3 (tr) |
HR (2) | HRP20130345T1 (tr) |
HU (1) | HUE040596T2 (tr) |
IL (1) | IL205741A0 (tr) |
LT (1) | LT2609916T (tr) |
MX (1) | MX2010005709A (tr) |
NZ (1) | NZ585440A (tr) |
PL (2) | PL2609916T3 (tr) |
PT (2) | PT2609916T (tr) |
SI (2) | SI2609916T1 (tr) |
TR (1) | TR201819564T4 (tr) |
WO (1) | WO2009068668A1 (tr) |
ZA (1) | ZA201003610B (tr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
EP2135607A1 (en) * | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
WO2010025322A2 (en) * | 2008-08-28 | 2010-03-04 | The Florida International University Board Of Trustees | Magnetic nanodelivery of therapeutic agents across the blood brain barrier |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
WO2011061304A1 (en) * | 2009-11-20 | 2011-05-26 | Pharnext | New diagnostic tools for charcot-marie-tooth disease |
HUE034866T2 (hu) | 2010-01-15 | 2018-03-28 | Inst Nat Sante Rech Med | NKCC inhibitorok az autizmus kezelésére |
EP2624832B1 (en) * | 2010-10-08 | 2017-09-27 | Vib Vzw | Hdac inhibitors to treat charcot-marie-tooth disease |
CN102464610B (zh) * | 2010-11-16 | 2014-07-30 | 北大方正集团有限公司 | 一种美替拉酮的制备方法 |
ES2716865T3 (es) | 2011-02-18 | 2019-06-17 | Scripps Research Inst | Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante |
WO2012114342A1 (en) | 2011-02-23 | 2012-08-30 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
UA113165C2 (xx) | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
CN102247324B (zh) * | 2011-07-14 | 2012-11-21 | 海南美兰史克制药有限公司 | 一种氟马西尼脂质体注射液 |
CN102887830B (zh) * | 2012-09-04 | 2013-11-27 | 苏州弘森药业有限公司 | 一种盐酸酚苄明的制备方法 |
WO2014063163A1 (en) | 2012-10-19 | 2014-04-24 | Block Jonathan D | Systems and methods for nerve mapping and monitoring |
US20150329483A1 (en) * | 2012-12-17 | 2015-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth |
LT3003268T (lt) | 2013-06-05 | 2018-12-10 | Pharnext | Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api) |
WO2015121218A1 (en) | 2014-02-11 | 2015-08-20 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
KR20160126045A (ko) * | 2014-02-24 | 2016-11-01 | 파넥스트 | 기계적 신경 손상을 치료하기 위한 신규 조성물 |
US20160339015A1 (en) * | 2015-05-20 | 2016-11-24 | Lupin Inc. | Oral pharmaceutical composition of methylergonovine |
AU2017229778A1 (en) * | 2016-03-09 | 2018-08-16 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting PMP22 expression |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
US11272871B2 (en) | 2016-07-14 | 2022-03-15 | Sidewaystrategies Llc | System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways |
WO2018076060A1 (en) * | 2016-10-26 | 2018-05-03 | Genea Ip Holdings Pty Ltd | Improved generation of muscle lineage cells and therapeutic uses thereof |
AU2018307964B2 (en) | 2017-07-28 | 2023-11-16 | Applied Therapeutics Inc. | Compositions and methods for treating galactosemia |
MX2021013511A (es) * | 2019-05-07 | 2022-02-23 | Univ Miami | Tratamiento y deteccion de neuropatias heredadas y trastornos asociados. |
JP2023524504A (ja) * | 2020-05-01 | 2023-06-12 | アプライド セラピューティクス, インコーポレイテッド | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
EP4019016A1 (en) * | 2020-12-24 | 2022-06-29 | Allaysis, LLC | Methods of administering intravenous baclofen |
US11523984B1 (en) * | 2021-11-12 | 2022-12-13 | Amneal Pharmaceuticals Llc | Compositions and methods of administering baclofen |
WO2023182288A1 (ja) * | 2022-03-22 | 2023-09-28 | 国立大学法人京都大学 | シャルコー・マリー・ツース病の治療または予防薬 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW427904B (en) | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
CN1152717C (zh) | 1997-09-30 | 2004-06-09 | 第一制药株式会社 | 口服给药制剂 |
WO2000017358A2 (en) * | 1998-09-22 | 2000-03-30 | Incyte Genomics, Inc. | Human chaperone proteins |
CA2345642A1 (en) | 1998-10-02 | 2000-04-13 | Celtrix Pharmaceuticals, Inc. | Methods for the treatment of non-thyroid disorders |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
WO2002049607A2 (en) | 2000-12-20 | 2002-06-27 | Firmenich Sa | Flavoured oral drug delivery system |
JP3805646B2 (ja) | 2001-05-25 | 2006-08-02 | 久光メディカル株式会社 | 医薬液剤 |
ATE477795T1 (de) * | 2001-07-04 | 2010-09-15 | Sun Pharma Advanced Res Co Ltd | Magenretentionssystem mit kontrollierter arzneimittelfreisetzung |
CA2478558C (en) * | 2002-03-14 | 2012-09-11 | Euro-Celtique, S.A. | Naltrexone hydrochloride compositions |
ES2327034T3 (es) * | 2002-03-26 | 2009-10-23 | Euro-Celtique S.A. | Composiciones recubiertas con gel de liberacion sostenida. |
FR2842422B1 (fr) | 2002-07-16 | 2006-06-30 | Univ Aix Marseille Ii | Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations |
JP2004049093A (ja) * | 2002-07-18 | 2004-02-19 | Meiji Milk Prod Co Ltd | 腸内酪酸上昇食品組成物および医薬品 |
US7109223B2 (en) | 2002-08-28 | 2006-09-19 | Merck & Co. Inc. | Oxazolidin-2-one and thiazolidin-2-one derivatives for use as EP4 receptor agonists in the treatment of glaucoma |
RU2224518C1 (ru) * | 2003-02-10 | 2004-02-27 | Дулькис Мария Дмитриевна | Жидкая лекарственная форма налтрексона |
ES2414084T3 (es) * | 2003-02-24 | 2013-07-18 | Pharmaceutical Productions Inc. | Sistema de administración de fármacos por vía transmucosa |
EP1615646B2 (en) * | 2003-04-08 | 2022-07-27 | Progenics Pharmaceuticals, Inc. | Pharmaceutical formulations containing methylnaltrexone |
WO2004091593A2 (en) * | 2003-04-14 | 2004-10-28 | Pain Therapeutics, Inc. | Methods for the treatment of pain comprising opioid antagonists |
WO2004103263A2 (en) * | 2003-05-22 | 2004-12-02 | Yeda Research And Development Co. Ltd. | Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases |
ATE464049T1 (de) * | 2003-09-25 | 2010-04-15 | Euro Celtique Sa | Pharmazeutische kombinationen von hydrocodon und naltrexon |
US20050191343A1 (en) | 2003-11-26 | 2005-09-01 | Shire Laboratories, Inc. | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
FR2865648B1 (fr) * | 2004-02-03 | 2006-06-30 | Philippe Perovitch | Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede |
US20050220863A1 (en) | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist |
JP2006131545A (ja) | 2004-11-05 | 2006-05-25 | Japan Science & Technology Agency | 神経因性疼痛治療剤 |
GB0509052D0 (en) | 2005-05-04 | 2005-06-08 | Aimsco Ltd | Combination therapy |
US20070099947A1 (en) | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
DE102006016990A1 (de) * | 2006-04-11 | 2007-10-18 | Hermann, Holger Lars, Dr. | Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen |
MX2008014320A (es) * | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
EP2021000A2 (en) * | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
EP2117517B1 (en) | 2007-01-11 | 2011-06-01 | XenoPort, Inc. | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
US20080255062A1 (en) | 2007-02-13 | 2008-10-16 | University Of Manitoba | Axon regeneration from adult sensory neurons |
US7806721B2 (en) * | 2007-08-02 | 2010-10-05 | Tyco Electronics Corporation | Patch panel modular jack assembly |
EP2065038A1 (en) | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
EP2135607A1 (en) | 2008-06-18 | 2009-12-23 | Pharnext | Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders |
EP2263665A1 (en) | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
US9393241B2 (en) | 2009-06-02 | 2016-07-19 | Pharnext | Compositions for treating CMT and related disorders |
EP2322163A1 (en) | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
IT1400067B1 (it) | 2010-05-21 | 2013-05-17 | Molteni & C | Spray nasale liquido contenente naltrexone a bassi dosaggi. |
CN103596562B (zh) | 2011-03-01 | 2016-06-01 | 法耐斯特公司 | 基于巴氯芬和阿坎酸的神经性障碍疗法 |
US9931326B2 (en) | 2011-03-29 | 2018-04-03 | Pharnext | Composition comprising torasemide and baclofen for treating neurological disorders |
LT3003268T (lt) | 2013-06-05 | 2018-12-10 | Pharnext | Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api) |
US10383870B2 (en) | 2016-06-10 | 2019-08-20 | Pharnext | Early treatment of CMT disease |
-
2007
- 2007-11-30 EP EP07301614A patent/EP2065038A1/en not_active Withdrawn
-
2008
- 2008-11-28 PL PL12196650T patent/PL2609916T3/pl unknown
- 2008-11-28 WO PCT/EP2008/066468 patent/WO2009068668A1/en active Application Filing
- 2008-11-28 EP EP08854467A patent/EP2211846B1/en active Active
- 2008-11-28 BR BRPI0819678A patent/BRPI0819678A2/pt not_active Application Discontinuation
- 2008-11-28 DK DK12196650.1T patent/DK2609916T3/en active
- 2008-11-28 US US12/744,962 patent/US8992891B2/en active Active
- 2008-11-28 ES ES08854467T patent/ES2408785T3/es active Active
- 2008-11-28 CA CA3031484A patent/CA3031484C/en active Active
- 2008-11-28 CN CN201410322856.0A patent/CN104257657B/zh active Active
- 2008-11-28 CA CA3031490A patent/CA3031490C/en active Active
- 2008-11-28 NZ NZ585440A patent/NZ585440A/en unknown
- 2008-11-28 EA EA201791669A patent/EA035711B1/ru not_active IP Right Cessation
- 2008-11-28 ES ES18203488T patent/ES2831855T3/es active Active
- 2008-11-28 MX MX2010005709A patent/MX2010005709A/es active IP Right Grant
- 2008-11-28 PT PT12196650T patent/PT2609916T/pt unknown
- 2008-11-28 DK DK08854467.1T patent/DK2211846T3/da active
- 2008-11-28 LT LTEP12196650.1T patent/LT2609916T/lt unknown
- 2008-11-28 AU AU2008328745A patent/AU2008328745B2/en active Active
- 2008-11-28 CN CN200880118498.4A patent/CN101883561B/zh active Active
- 2008-11-28 EP EP12196650.1A patent/EP2609916B1/en active Active
- 2008-11-28 EA EA201000914A patent/EA019402B1/ru not_active IP Right Cessation
- 2008-11-28 KR KR1020107014240A patent/KR101546031B1/ko active IP Right Grant
- 2008-11-28 TR TR2018/19564T patent/TR201819564T4/tr unknown
- 2008-11-28 SI SI200832028T patent/SI2609916T1/sl unknown
- 2008-11-28 ES ES12196650T patent/ES2703508T3/es active Active
- 2008-11-28 CA CA2705408A patent/CA2705408C/en active Active
- 2008-11-28 PL PL08854467T patent/PL2211846T3/pl unknown
- 2008-11-28 EA EA201301078A patent/EA032767B1/ru not_active IP Right Cessation
- 2008-11-28 HU HUE12196650A patent/HUE040596T2/hu unknown
- 2008-11-28 PT PT88544671T patent/PT2211846E/pt unknown
- 2008-11-28 EP EP18203488.4A patent/EP3459535B1/en active Active
- 2008-11-28 JP JP2010535399A patent/JP5953000B2/ja active Active
- 2008-11-28 SI SI200830954T patent/SI2211846T1/sl unknown
-
2010
- 2010-05-13 IL IL205741A patent/IL205741A0/en active IP Right Grant
- 2010-05-21 ZA ZA2010/03610A patent/ZA201003610B/en unknown
-
2013
- 2013-04-17 HR HRP20130345AT patent/HRP20130345T1/hr unknown
- 2013-05-02 CY CY20131100368T patent/CY1113980T1/el unknown
-
2015
- 2015-02-20 US US14/627,229 patent/US20150157626A1/en not_active Abandoned
-
2016
- 2016-03-01 JP JP2016039032A patent/JP6608309B2/ja active Active
-
2018
- 2018-02-26 JP JP2018031658A patent/JP2018109043A/ja active Pending
- 2018-04-30 US US15/966,848 patent/US10322101B2/en active Active
- 2018-08-06 US US16/055,710 patent/US10441558B2/en active Active
- 2018-08-06 US US16/055,797 patent/US10463640B2/en active Active
- 2018-12-18 HR HRP20182147TT patent/HRP20182147T8/hr unknown
- 2018-12-19 CY CY20181101374T patent/CY1121183T1/el unknown
-
2019
- 2019-04-17 JP JP2019078588A patent/JP2019142917A/ja active Pending
- 2019-09-27 US US16/586,136 patent/US20200155491A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR201819564T4 (tr) | Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar. | |
EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
EA201071243A1 (ru) | Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом | |
EA201200686A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера | |
EA201101686A1 (ru) | Новые композиции для лечения шмт и связанных с ней расстройств | |
MX2014002668A (es) | Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas. | |
MY161656A (en) | Therapeutic use of diaminophenothiazines | |
MX2018009945A (es) | Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad. | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
EA201001639A1 (ru) | Композиции и способы их получения и применения | |
EA201000673A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ | |
MX2010002732A (es) | Inhibidores de f1f0-atpasa y metodos relacionados. | |
EA201270575A1 (ru) | Соединения | |
EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
MX2011006006A (es) | Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos. | |
GB2503852A (en) | Compounds for the treatment of neuropsychiatric disorders | |
MX370721B (es) | Compuestos y composiciones novedosas para atacar las células madre del cáncer. | |
EA201170356A1 (ru) | Полиморфные и аморфные формы лакозамида и аморфные композиции | |
MY186456A (en) | Quinazoline carboxamide azetidines | |
EA201170425A1 (ru) | Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения | |
EA201190209A1 (ru) | Соединения для лечения метаболических расстройств | |
EA201190208A1 (ru) | Соединения для лечения метаболических расстройств | |
MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
MX349254B (es) | Compuestos para el tratamiento del sindrome metabolico. |